The small market for drugs used to treat rare diseases often makes the drugs extremely expensive. Consequently, many pharmaceutical companies may stop manufacturing these drugs or may not initiate research and development into new therapies. Moving these drugs from bench to bedside requires a
No takes yet. Share an insight, caveat, or question.
Panju et al. (2010) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: